Triamcinolone acetonide

Triamcinolone acetonide
Clinical data
Trade namesKenalog, Nasacort, Xipere, others
AHFS/Drugs.comMonograph
MedlinePlusa601124
License data
Pregnancy
category
  • AU: B3/ A
Routes of
administration		Topical, joint injection, nasal
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismLiver
ExcretionUrine (75%) and feces (25%)
Identifiers
  • (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS)-4b-fluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.000.863 Edit this at Wikidata
Chemical and physical data
FormulaC24H31FO6
Molar mass434.504 g·mol−1
3D model (JSmol)
Melting point290 to 294 °C (554 to 561 °F)
  • C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O
  • InChI=1S/C24H31FO6/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,25)17(28)11-22(16,4)24(19,31-20)18(29)12-26/h7-9,15-17,19,26,28H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1 checkY
  • Key:YNDXUCZADRHECN-JNQJZLCISA-N checkY
 ☒NcheckY (what is this?)  (verify)

Triamcinolone acetonide, sold under the brand name Kenalog among others, is a synthetic corticosteroid medication used topically to treat various skin conditions,[13] to relieve the discomfort of mouth sores, and by injection into joints to treat various joint conditions. It is also injected into lesions to treat inflammation in some parts of the body, particularly the skin. In nasal spray form, it is used to treat allergic rhinitis. It is used for the treatment of macular edema associated with uveitis.[11] It is a more potent derivative of triamcinolone, and is about eight times as potent as prednisone.[14]

Most forms of triamcinolone acetonide are prescription drugs. In 2014, the U.S. Food and Drug Administration (FDA) made triamcinolone acetonide an over-the-counter drug in the United States in nasal spray form under the brand name Nasacort.[14] It is available as a generic medication.[15]

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  2. ^ "KENALOG IN ORABASE triamcinolone acetonide". Australian Register of Therapeutic Goods (ARTG). Australian Government. ARTG ID 19205.
  3. ^ "KENACORT A10 triamcinolone acetonide". Australian Register of Therapeutic Goods (ARTG).
  4. ^ "NASACORT AQ Triamcinolone acetonide". Annual charge exemptions dataset. Department of Health and Aged Care, Australian Government.
  5. ^ "Aristocort C Product information". Health Canada. 25 April 2012. Retrieved 23 December 2022.
  6. ^ "Nasacort Allergy 24HR Product information". Health Canada. 25 April 2012. Retrieved 23 December 2022.
  7. ^ "Adcortyl Intra-Articular/Intradermal Injection 10mg/ml - Summary of Product Characteristics (SmPC)". (emc). 8 October 2021. Retrieved 23 December 2022.
  8. ^ "Kenalog Intra-articular / Intramuscular Injection - Summary of Product Characteristics (SmPC)". (emc). 8 April 2022. Retrieved 23 December 2022.
  9. ^ "Nasacort 55 micrograms/dose, nasal spray, suspension - Summary of Product Characteristics (SmPC)". (emc). 1 November 2021. Retrieved 23 December 2022.
  10. ^ "Nasacort Allergy Relief for Adults 55 micrograms/dose, nasal spray, suspension - Summary of Product Characteristics (SmPC)". (emc). 1 November 2021. Archived from the original on 23 December 2022. Retrieved 23 December 2022.
  11. ^ a b "Xipere- triamcinolone acetonide injection, suspension". DailyMed. Retrieved 19 December 2021.
  12. ^ "Active substance(s): triamcinolone (topical and nasal formulations)" (PDF). List of nationally authorised medicinal products. European Medicines Agency. 8 March 2018.
  13. ^ "Triamcinolone Topical". MedlinePlus. Retrieved 12 November 2020.
  14. ^ a b "Nasacort Allergy 24HR- triamcinolone acetonide spray, metered". DailyMed. 3 February 2014. Retrieved 12 November 2020.
  15. ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Retrieved 6 March 2023.